Yong Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yong Chen has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Fei Wang
Fudan University
3 shared publications - Li Zhao
Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA
3 shared publications - Rui Chen
Department of Ophthalmology, Center for Translational Vision Research, Irvine School of Medicine, University of California, Irvine, CA 92697, USA
3 shared publications - Mingchu Xu
Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA
2 shared publications - Peter Ronghan Wang
Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA
2 shared publications - Xia Wang
Baylor College of Medicine
2 shared publications
Latest Publications
- Open Access
- 26 November 2018
- Published by Springer Nature in Genome Biology
- Vol. 19 (1) , 203
GRIPT: a novel case-control analysis method for Mendelian disease gene discovery
Despite rapid progress of next-generation sequencing (NGS) technologies, the disease-causing genes underpinning about half of all Mendelian diseases remain elusive. One main challenge is the high genetic heterogeneity of Mendelian diseases in which similar phenotypes are caused by different genes and each gene only accounts for a small proportion of the patients. To overcome this gap, we developed a novel method, the Gene Ranking, Identification and Prediction Tool (GRIPT), for performing case-control analysis of NGS data. Analyses of simulated and real datasets show that GRIPT is well-powered for disease gene discovery, especially for diseases with high locus heterogeneity.
- 26 November 2018
- Published by Springer Nature in Genome Biology
- Vol. 19 (1) , 203
Open AccessGRIPT: a novel case-control analysis method for Mendelian disease gene discovery
Despite rapid progress of next-generation sequencing (NGS) technologies, the disease-causing genes underpinning about half of all Mendelian diseases remain elusive. One main challenge is the high genetic heterogeneity of Mendelian diseases in which similar phenotypes are caused by different genes and each gene only accounts for a small proportion of the patients. To overcome this gap, we developed a novel method, the Gene Ranking, Identification and Prediction Tool (GRIPT), for performing case-control analysis of NGS data. Analyses of simulated and real datasets show that GRIPT is well-powered for disease gene discovery, especially for diseases with high locus heterogeneity.
- Open Access
GRIPT: A novel case-control analysis method for Mendelian disease gene discovery
Despite rapid progress of next-generation sequencing (NGS) technologies, the disease-causing genes underpinning about 50% of Mendelian diseases remain elusive. One main challenge is the high genetic heterogeneity of Mendelian diseases in which similar phenotypes are caused by different genes and each gene only accounts for a small proportion of the patients. To overcome this gap, we developed a novel method, the Gene Ranking, Identification and Prediction Tool (GRIPT), for performing case-control analysis of NGS data. Analyses of simulated and real datasets show that GRIPT is well-powered for disease gene discovery, especially for diseases with high locus heterogeneity.
Open AccessGRIPT: A novel case-control analysis method for Mendelian disease gene discovery
Despite rapid progress of next-generation sequencing (NGS) technologies, the disease-causing genes underpinning about 50% of Mendelian diseases remain elusive. One main challenge is the high genetic heterogeneity of Mendelian diseases in which similar phenotypes are caused by different genes and each gene only accounts for a small proportion of the patients. To overcome this gap, we developed a novel method, the Gene Ranking, Identification and Prediction Tool (GRIPT), for performing case-control analysis of NGS data. Analyses of simulated and real datasets show that GRIPT is well-powered for disease gene discovery, especially for diseases with high locus heterogeneity.
- Open Access
- 3 March 2017
- Published by Springer Nature in BMC Bioinformatics
- Vol. 18 (1) , 1-9
SeqCNV: a novel method for identification of copy number variations in targeted next-generation sequencing data
Targeted next-generation sequencing (NGS) has been widely used as a cost-effective way to identify the genetic basis of human disorders. Copy number variations (CNVs) contribute significantly to human genomic variability, some of which can lead to disease. However, effective detection of CNVs from targeted capture sequencing data remains challenging. Here we present SeqCNV, a novel CNV calling method designed to use capture NGS data. SeqCNV extracts the read depth information and utilizes the maximum penalized likelihood estimation (MPLE) model to identify the copy number ratio and CNV boundary. We applied SeqCNV to both bacterial artificial clone (BAC) and human patient NGS data to identify CNVs. These CNVs were validated by array comparative genomic hybridization (aCGH). SeqCNV is able to robustly identify CNVs of different size using capture NGS data. Compared with other CNV-calling methods, SeqCNV shows a significant improvement in both sensitivity and specificity.
- 3 March 2017
- Published by Springer Nature in BMC Bioinformatics
- Vol. 18 (1) , 1-9
Open AccessSeqCNV: a novel method for identification of copy number variations in targeted next-generation sequencing data
Targeted next-generation sequencing (NGS) has been widely used as a cost-effective way to identify the genetic basis of human disorders. Copy number variations (CNVs) contribute significantly to human genomic variability, some of which can lead to disease. However, effective detection of CNVs from targeted capture sequencing data remains challenging. Here we present SeqCNV, a novel CNV calling method designed to use capture NGS data. SeqCNV extracts the read depth information and utilizes the maximum penalized likelihood estimation (MPLE) model to identify the copy number ratio and CNV boundary. We applied SeqCNV to both bacterial artificial clone (BAC) and human patient NGS data to identify CNVs. These CNVs were validated by array comparative genomic hybridization (aCGH). SeqCNV is able to robustly identify CNVs of different size using capture NGS data. Compared with other CNV-calling methods, SeqCNV shows a significant improvement in both sensitivity and specificity.